On Friday, Alembic Pharmaceuticals informed the exchanges that it has received final approval from US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Doxepin Hydrochloride capsules, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg & 100 mg.